Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Change in Account Payables (2016 - 2025)

Adma Biologics (ADMA) has disclosed Change in Account Payables for 13 consecutive years, with -$2.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Account Payables fell 155.89% year-over-year to -$2.2 million, compared with a TTM value of $2.3 million through Dec 2025, down 43.86%, and an annual FY2025 reading of $2.3 million, down 43.86% over the prior year.
  • Change in Account Payables was -$2.2 million for Q4 2025 at Adma Biologics, up from -$4.9 million in the prior quarter.
  • Across five years, Change in Account Payables topped out at $13.8 million in Q3 2022 and bottomed at -$12.0 million in Q4 2022.
  • Average Change in Account Payables over 5 years is $623750.0, with a median of $66000.0 recorded in 2023.
  • The sharpest move saw Change in Account Payables soared 16280.0% in 2024, then plummeted 401.36% in 2025.
  • Year by year, Change in Account Payables stood at -$4.9 million in 2021, then plummeted by 146.61% to -$12.0 million in 2022, then skyrocketed by 141.73% to $5.0 million in 2023, then decreased by 21.07% to $3.9 million in 2024, then tumbled by 155.89% to -$2.2 million in 2025.
  • Business Quant data shows Change in Account Payables for ADMA at -$2.2 million in Q4 2025, -$4.9 million in Q3 2025, and $9.3 million in Q2 2025.